Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the Omicron-predominant epidemic wave in the Philippines: a test-negative case–control study

Background CoronaVac (Sinovac) was initially effective against symptomatic COVID-19 and severe outcomes, but its performance against the immune-evasive Omicron variant remains uncertain. This study evaluated the effectiveness of CoronaVac against hospitalized COVID-19 among Filipino adults during th...

Full description

Bibliographic Details
Published in:	Expert Review of Vaccines
Main Authors:	Kristal An Agrupis, Michelle Ylade, Yang Yang Qi, Maria Vinna Crisostomo, Jedas Veronica Daag, Gianne Lariz Magsakay, Jude Raphael Lo, Kiarah Louise Florendo, March Helena Jane Lopez, Jayne Marie Enriquez, Irish Lobitaña, Gretchen Bonita Ranada, Regina Alfonso, Mitzi Marie Chua, Mitzie Lou Osabel, Mary Ann Igoy-Bacay, Carren Anne Bocaling, Lorenz Von Seidlein, Xuanyi Wang, Jacqueline Deen
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	COVID-19 CoronaVac Sinovac inactivated vaccines vaccine effectiveness SARS-CoV-2
Online Access:	https://www.tandfonline.com/doi/10.1080/14760584.2025.2539889

Similar Items

SARS-CoV-2 Alpha Variant Infection of a Patient Immunized by Inactive Sinovac (CoronaVac) Vaccine
by: Ozverel Cenk Serhan, et al.
Published: (2022-01-01)

HEALTH-RELATED QUALITY OF LIFE POST-SINOVAC VACCINE IN COMMUNITIES IN TAMPAN DISTRICT AND MARPOYAN DISTRICT, PEKANBARU CITY
by: Seftika Sari, et al.
Published: (2023-03-01)

Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report
by: Wanakorn Rattanawong, et al.
Published: (2021-08-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
by: Gulsum Iclal Bayhan, et al.
Published: (2022-01-01)

Sinovac Vaccine According to the Fatwa of the Indonesian Ulema Council Number 2 of 2021 Sharia Maqāṣid Perspective
by: Siti Aisyah Kara, et al.
Published: (2023-08-01)

Efficacy and safety of Sinovac vaccine administered in patients undergoing hemodialysis
by: Davut Akin, et al.
Published: (2022-12-01)

Manifestations of adverse events post Sinovac vaccine immunization at Wirasakti Hospital, Kupang
by: Aries H. Basri, et al.
Published: (2023-04-01)

Fikih Prioritas dalam Fatwa Kehalalan Vaksin Covid-19 di Indonesia
by: Wahyu Akbar, et al.
Published: (2022-09-01)

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
by: Bothamai Dechates, et al.
Published: (2023-03-01)

Survey of the side effects of most commonly administered covid-19 vaccines in population of Lahore
by: Marriam Sheraz, et al.
Published: (2025-03-01)

Vaccine Adverse Events Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe
by: Azure Tariro Makadzange, et al.
Published: (2022-10-01)

Effect of Pfizer/BioNTech and Sinovac/CoronaVac Vaccines on Semen Parameters in Infertile Patients with Idiopathic Infertility: A Single-center Cohort Study
by: Eyüp Dil
Published: (2023-09-01)

A 32-Year-Old Coronary Thrombus Case Found during the COVID-19 Pandemic: Could It Be Caused By Sinovac Inactivated Vaccine Or COVID-19 Late-Term Complication?
by: Adem Aktan, et al.
Published: (2021-01-01)

Durability of S-RBD IgG Antibody Levels after Sinovac Vaccination in Healthcare Workers
by: Jusak Nugraha, et al.
Published: (2022-09-01)

Analyses the Construction of the Indonesian Ulema Council Fatwa on the Halalness of the Sinovac Covid-19 Vaccine using the Jasser Auda’s Perspective of Islamic Law Development Models
by: Muhammad Abduh, et al.
Published: (2022-04-01)

COVID-19 Vaccine Take-up Rate, Safety and Tolerability in Patients with Epilepsy
by: Firdevs Ezgi Uçan Tokuç, et al.
Published: (2023-06-01)

Enterovirus A71 Vaccines
by: Mei-Ling Li, et al.
Published: (2021-02-01)

Waning anti-SARS-CoV-2 receptor-binding domain total antibody in CoronaVac-vaccinated individuals in Indonesia [version 2; peer review: 2 approved]
by: Samsul Anwar, et al.
Published: (2023-04-01)

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study
by: Yuxiao Wang, et al.
Published: (2023-03-01)

Factors Associated with SARS-CoV-2 Antibody Titer After Sinovac Vaccination Among Health Care Workers
by: Theresia Santi, et al.
Published: (2022-01-01)

Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
by: Ximena Aguilera, et al.
Published: (2022-06-01)

Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
by: Chutima Seree-aphinan, et al.
Published: (2021-12-01)

Impact of the COVID-19 pandemic and a supertyphoon: A quantitative study in Cebu, Philippines.
by: Michelle Ylade, et al.
Published: (2024-01-01)

Kejadian Breakthrough Infection Pasca Vaksinasi Dosis 2 Sinovac pada Tenaga Kesehatan RSUD Arifin Achmad
by: Agung Ramadhan, et al.
Published: (2023-04-01)

Association between Gut Microbiota Composition and Long-Term Vaccine Immunogenicity following Three Doses of CoronaVac
by: Li-Na Zhang, et al.
Published: (2024-03-01)

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
by: Meliha Cagla Sonmezer, et al.
Published: (2022-07-01)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
by: Lairun Jin, et al.
Published: (2022-11-01)

Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved?
by: Héctor Serrano-Coll, et al.
Published: (2022-01-01)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
by: Somruedee Chatsiricharoenkul, et al.
Published: (2022-10-01)

Body Mass Index, Age, and Gender Affect CoronaVac Vaccine Antibody Response
by: Ayfer ÇOLAK, et al.
Published: (2022-08-01)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
by: Ayakarn Ruenkham, et al.
Published: (2023-09-01)

CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes
by: Laisuan W, et al.
Published: (2021-10-01)

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study
by: Hakan Demirhindi, et al.
Published: (2022-04-01)

Dermatological adverse effects of COVID-19 vaccines
by: Elçin Akdaş, et al.
Published: (2022-12-01)

Side effects of CoronaVac® COVID-19 vaccination: Investigation in North Jakarta district public health center communities in Indonesia
by: Diana Laila Ramatillah, et al.
Published: (2024-05-01)

Experience and opinions of healthcare professionals on COVID-19 and inactive COVID-19 Vaccine (Coronavac, developed by sinovac of china)
by: Burcu Kayhan Tetik, et al.
Published: (2022-12-01)

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
by: Sutima Luangdilok, et al.
Published: (2022-09-01)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
by: Çiğdem Erol, et al.
Published: (2023-07-01)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
by: Kristi Tsz-Wan Lai, et al.
Published: (2022-04-01)